The test measures IgG antibodies directed to the spike protein of the virus and has demonstrated 99.9 percent specificity and 98.9 percent sensitivity.
The lateral flow test is designed to detect immunoglobulin G antibodies against SARS-CoV-2 in a finger prick blood sample and returns results in 20 minutes.
Leinco will use the antibodies for diagnostic applications and will make the antibodies commercially available as part of their research tools catalog.